Astra Zeneca LP Us Revenue and Competitors
Estimated Revenue & Valuation
- Astra Zeneca LP Us's estimated annual revenue is currently $65.1M per year.
- Astra Zeneca LP Us's estimated revenue per employee is $201,000
Employee Data
- Astra Zeneca LP Us has 324 Employees.
- Astra Zeneca LP Us grew their employee count by -3% last year.
Astra Zeneca LP Us's People
Name | Title | Email/Phone |
---|
Astra Zeneca LP Us Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $44.4M | 221 | 31% | N/A | N/A |
#2 | $10.3M | 51 | -27% | N/A | N/A |
#3 | $83.2M | 414 | 6% | N/A | N/A |
#4 | $59.9M | 298 | -9% | N/A | N/A |
#5 | $9.4M | 47 | 42% | N/A | N/A |
#6 | $136.3M | 678 | -8% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $0.7M | 7 | 0% | N/A | N/A |
#9 | $3M | 15 | 50% | N/A | N/A |
#10 | $9.6M | 48 | 7% | N/A | N/A |
What Is Astra Zeneca LP Us?
Astra Zeneca LP Us is a Pharmaceuticals company located in 1800 Concord Pike, Wilmington, Delaware, United States.
keywords:N/AN/A
Total Funding
324
Number of Employees
$65.1M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Astra Zeneca LP Us News
2022-04-06 - Daiichi Owes Seagen $41.8 Million Over Cancer Treatment ...
AstraZeneca, which markets Enhertu in the U.S., intervened in the suit. ... 2022 Bloomberg L.P. All rights reserved. Used with permission.
2022-04-06 - Daiichi Gets Rare Patent Board Rehearing in Drug Dispute (1)
Daiichi Sankyo Co. and AstraZeneca Pharmaceuticals LP were granted a rare administrative patent tribunal rehearing after the board rejected...
2022-03-22 - Oncology Overview: Acalabrutinib (Calquence) for Chronic ...
Acalabrutinib (Calquence; AstraZeneca Pharmaceuticals LP) is a ... The American Cancer Society estimates more than 60,000 new cases of...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $53.3M | 328 | -4% | $69M |
#2 | $119.6M | 330 | 0% | N/A |
#3 | $15M | 336 | 1% | N/A |
#4 | $86.4M | 337 | 2% | N/A |
#5 | $69.5M | 346 | -3% | N/A |